This study is testing a new medicine called Sutetinib Maleate for people with advanced non-small cell lung cancer (NSCLC). NSCLC is a type of lung cancer that often spreads to other parts of the body. Sutetinib is a drug that stops a protein called EGFR from helping cancer cells grow. The study is open-label, meaning both the doctors and patients know what treatment is being given. It is for patients with specific changes (mutations) in their EGFR gene. These mutations are different from common ones usually treated with other drugs.

Key Points:

• Participation Requirements: Participants must be 18 or older, have specific EGFR mutations, and not have had certain cancer treatments recently.
• Study Details: The study is at multiple locations and helps researchers see if Sutetinib is safe and works well for this type of cancer.
• Exclusions: People with some health issues, like certain lung diseases or those who have used similar drugs before, cannot join.